Literature DB >> 20596864

Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?

Sandip Basu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20596864     DOI： 10.1007/s00259-010-1530-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.

Authors:  John R Buscombe; Jaroslaw B Cwikla; Martyn E Caplin; Andrew J W Hilson
Journal:  Nucl Med Commun       Date:  2005-11       Impact factor: 1.690

2.  Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

Authors:  J J Mukherjee; G A Kaltsas; N Islam; P N Plowman; R Foley; J Hikmat; K E Britton; P J Jenkins; S L Chew; J P Monson; G M Besser; A B Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  2001-07       Impact factor: 3.478

3.  131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.

Authors:  Mark S Sywak; Janice L Pasieka; Alexander McEwan; Greg Kline; Otto Rorstad
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

4.  Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzylguanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false "reverse" discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapy.

Authors:  S Basu; N Nair
Journal:  Br J Radiol       Date:  2006-08       Impact factor: 3.039

Review 5.  Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.

Authors:  J B Bomanji; W Wong; M N Gaze; A Cassoni; W Waddington; J Solano; P J Ell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-06       Impact factor: 4.126

Review 6.  Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.

Authors:  D Taggart; S Dubois; K K Matthay
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 2.346

7.  131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.

Authors:  Gonca Kara Gedik; Cornelis A Hoefnagel; Evert Bais; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-11       Impact factor: 9.236

Review 8.  Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.

Authors:  Ernst J Postema; Alexander J B McEwan
Journal:  Cancer Biother Radiopharm       Date:  2009-10       Impact factor: 3.099

9.  Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.

Authors:  Jan de Kraker; Kees A Hoefnagel; Arnauld C Verschuur; Berthe van Eck; Hanneke M van Santen; Huib N Caron
Journal:  Eur J Cancer       Date:  2008-02-11       Impact factor: 9.162
  9 in total
  1 in total

1.  Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders.

Authors:  Sandip Basu; Thomas C Kwee; Robert Gatenby; Babak Saboury; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.